Oklahoma 2022 2022 Regular Session

Oklahoma Senate Bill SB1152 Introduced / Bill

Filed 12/30/2021

                     
 
 
Req. No. 2407 	Page 1  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
STATE OF OKLAHOMA 
 
2nd Session of the 58th Legislature (2022) 
 
SENATE BILL 1152 	By: Standridge 
 
 
 
 
 
AS INTRODUCED 
 
An Act relating to the Uniform Controlled Dangerous 
Substances Act; amending 63 O. S. 2021, Section 2-204, 
which relates to Schedule I; modifying inclusions; 
and providing an effective date . 
 
 
 
 
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA: 
SECTION 1.     AMENDATORY     63 O.S. 2021, Section 2 -204, is 
amended to read as follows: 
Section 2-204. The controlled substances listed in this section 
are included in Schedule I and include any material, compound, 
mixture or preparation that contains any quan tity of the following 
hallucinogenic substance s, their salts, isomers and salts of 
isomers, unless specifically excepted, when the existence of these 
salts, isomers and salts of isomers is possible within the specific 
chemical designation. 
A.  Any of the following opiates, including their isomers, 
esters, ethers, salts, and salts of isomers, esters, a nd ethers, 
unless specifically excepted, when the existence of these isomers,   
 
 
Req. No. 2407 	Page 2  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
esters, ethers, and salts is possible within the specific chemical 
designation: 
1.  Acetylmethadol; 
2.  Allylprodine; 
3.  Alphacetylmethadol; 
4.  Alphameprodine; 
5.  Alphamethadol; 
6.  Benzethidine; 
7.  Betacetylmethadol; 
8.  Betameprodine; 
9.  Betamethadol; 
10.  Betaprodine; 
11.  Clonitazene; 
12.  Dextromoramide; 
13.  Dextrorphan (except its methyl ether); 
14.  Diampromide; 
15.  Diethylthiambutene; 
16.  Dimenoxadol; 
17.  Dimepheptanol; 
18. Dimethylthiambutene; 
19.  Dioxaphetyl butyrate; 
20.  Dipipanone; 
21.  Ethylmethylthiambutene; 
22.  Etonitazene;   
 
 
Req. No. 2407 	Page 3  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
23.  Etoxeridine; 
24.  Furethidine; 
25.  Hydroxypethidine; 
26.  Ketobemidone; 
27.  Levomoramide; 
28.  Levophenacylmorphan; 
29.  Metonitazene; 
29. 30. Morpheridine; 
30. 31. Noracymethadol; 
31. 32. Norlevorphanol; 
32. 33. Normethadone; 
33. 34. Norpipanone; 
34. 35. Phenadoxone; 
35. 36. Phenampromide; 
36. 37. Phenomorphan; 
37. 38. Phenoperidine; 
38. 39. Piritramide; 
39. 40. Proheptazine; 
40. 41. Properidine; 
41. 42. Racemoramide; or 
42. 43. Trimeperidine. 
B.  Any of the following opium derivatives, their salts, 
isomers, and salts of isomers, unless specifically excepted, when   
 
 
Req. No. 2407 	Page 4  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
the existence of these salts, isomers, and salts of isomers i s 
possible within the specific chemical de signation: 
1.  Acetorphine; 
2.  Acetyldihydrocodeine; 
3.  Benzylmorphine; 
4.  Codeine methylbromide; 
5.  Codeine-N-Oxide; 
6.  Cyprenorphine; 
7.  Desomorphine; 
8.  Dihydromorphine; 
9.  Etorphine; 
10.  Heroin; 
11.  Hydromorphinol; 
12.  Methyldesorphine; 
13.  Methylhydromorphine; 
14.  Morphine methylbromide; 
15.  Morphine methylsulfonate; 
16.  Morphine-N-Oxide; 
17.  Myrophine; 
18.  Nicocodeine; 
19.  Nicomorphine; 
20.  Normorphine; 
21.  Phoclodine; 
22.  Thebacon;   
 
 
Req. No. 2407 	Page 5  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
23.  N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide 
(Acetyl fentanyl); 
24.  N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butenamide 
(Crotonyl fentanyl); 
25.  N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-
furancarboxamide (Furanyl fentanyl); 
26.  N-phenyl-1-(2-phenylethyl)-4-piperidinamine (4-ANPP); 
27.  N-(1-phenethylpiperidin-4-yl)-N-
phenylcyclopropanecarboxamide (Cyclopropyl fentanyl); or 
28.  N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide 
(Butyrl fentanyl). 
C.  Any material, compound, mixture , or preparation which 
contains any quantity of the following hal lucinogenic substances, 
their salts, isomers, and salts of isomers, unless specifically 
excepted, when the existence of these salts, isomers, and salts of 
isomers is possible within the speci fic chemical designation: 
1.  Methcathinone; 
2.  3, 4-methylenedioxy amphetamine; 
3.  3, 4-methylenedioxy methamphetamine; 
4.  5-methoxy-3, 4-methylenedioxy amphetamine; 
5.  3, 4, 5-trimethoxy amphetamine; 
6.  Bufotenine; 
7.  Diethyltryptamine; 
8.  Dimethyltryptamine;   
 
 
Req. No. 2407 	Page 6  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
9.  4-methyl-2, 5-dimethoxyamphetamine; 
10.  Ibogaine; 
11.  Lysergic acid diethylamide; 
12.  Marijuana; 
13.  Mescaline; 
14.  N-benzylpiperazine; 
15.  N-ethyl-3-piperidyl benzilate; 
16.  N-methyl-3-piperidyl benzilate; 
17.  Psilocybin; 
18.  Psilocyn; 
19.  2, 5 dimethoxyamphetamine; 
20. 4 Bromo-2, 5-dimethoxyamphetamine; 
21.  4 methoxyamphetamine; 
22.  Cyclohexamine; 
23.  Salvia Divinorum; 
24.  Salvinorin A; 
25.  Thiophene Analog of Phencycli dine. Also known as: 1-(1-(2-
thienyl) cyclohexyl) pip eridine; 2-Thienyl Analog of Phencyclidine ; 
TPCP, TCP; 
26.  Phencyclidine (PCP); 
27.  Pyrrolidine Analog for Phencyclidine .  Also known as 1-(1-
Phenylcyclohexyl) - Pyrrolidine, PCPy, PHP; 
28.  1-(3-trifluoromethylphenyl) piperazine; 
29.  Flunitrazepam;   
 
 
Req. No. 2407 	Page 7  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
30. B-hydroxy-amphetamine; 
31.  B-ketoamphetamine; 
32.  2,5-dimethoxy-4-nitroamphetamine; 
33.  2,5-dimethoxy-4-bromophenethylamine; 
34.  2,5-dimethoxy-4-chlorophenethylamine; 
35.  2,5-dimethoxy-4-iodoamphetamine; 
36.  2,5-dimethoxy-4-iodophenethylamine; 
37.  2,5-dimethoxy-4-methylphenethylamine; 
38. 2,5-dimethoxy-4-ethylphenethylamine; 
39.  2,5-dimethoxy-4-fluorophenethylamine; 
40.  2,5-dimethoxy-4-nitrophenethylamine; 
41.  2,5-dimethoxy-4-ethylthio-phenethylamine; 
42.  2,5-dimethoxy-4-isopropylthio-phenethylamine; 
43.  2,5-dimethoxy-4-propylthio-phenethylamine; 
44.  2,5-dimethoxy-4-cyclopropylmethylthio -phenethylamine; 
45.  2,5-dimethoxy-4-tert-butylthio-phenethylamine; 
46.  2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine; 
47.  5-methoxy-N, N-dimethyltryptamine; 
48.  N-methyltryptamine; 
49.  A-ethyltryptamine; 
50.  A-methyltryptamine; 
51.  N, N-diethyltryptamine; 
52.  N, N-diisopropyltryptamine; 
53.  N, N-dipropyltryptamine;   
 
 
Req. No. 2407 	Page 8  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
54.  5-methoxy-a-methyltryptamine; 
55.  4-hydroxy-N, N-diethyltryptamine; 
56.  4-hydroxy-N, N-diisopropyltryptamine; 
57.  5-methoxy-N, N-diisopropyltryptamine; 
58.  4-hydroxy-N-isopropyl-N-methyltryptamine; 
59.  3,4-Methylenedioxymethcathinone (Methylone); 
60.  3,4-Methylenedioxypyrovalerone (MDPV); 
61.  4-Methylmethcathinone (Mephedron e); 
62.  4-methoxymethcathinone; 
63.  4-Fluoromethcathinone; 
64.  3-Fluoromethcathinone; 
65.  1-(8-bromobenzo 1,2-b;4,5-b’ difuran-4-yl)-2-aminopropane; 
66.  2,5-Dimethoxy-4-chloroamphetamine; 
67.  4-Methylethcathinone; 
68.  Pyrovalerone; 
69.  N,N-diallyl-5-methoxytryptamine; 
70.  3,4-Methylenedioxy-N-ethylcathinone (Ethylone); 
71.  B-keto-N-Methylbenzodioxolylbutanamine (Butylon e); 
72.  B-keto-Methylbenzodioxolylpentanamine (Pentylone); 
73.  Alpha-Pyrrolidinopentiophenone; 
74.  4-Fluoroamphetamine; 
75.  Pentedrone; 
76.  4’-Methyl-a-pyrrolidinohexaphenone; 
77.  2,5-dimethoxy-4-(n)-propylphenethylamine;   
 
 
Req. No. 2407 	Page 9  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
78.  2,5-dimethoxyphenethylamine; 
79.  1,4-Dibenzylpiperazine; 
80.  N,N-Dimethylamphetamine; 
81.  4-Fluoromethamphetamine; 
82.  4-Chloro-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine 
(25C-NBOMe); 
83.  4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine 
(25I-NBOMe); 
84.  4-Bromo-2,5-dimethoxy-N-(2-methoxybenzy)phenethylamine 
(25B-NBOMe); 
85.  1-(4-Fluorophenyl)piperazine; 
86.  Methoxetamine; 
87.  3,4-dichloro-N[2-dimethylamino)cyclohexyl] -N-
methylbenzamide; 
88.  N-ethyl hexadrone; 
89.  Isopropyl-U-47700; 
90.  Para-fluorobutyrl fentanyl; 
91.  Fluoro isobutryrl fentanyl; 
92.  3-Hydroxy Phencyclidine (PCP); or 
93.  3-methoxy Phencyclidine (PCP) ; 
94.  Flualprazolam; or 
95.  Flubromazolam. 
D.  Unless specifically excepted or unless listed in a di fferent 
schedule, any material, compound, mixture, or prepara tion which   
 
 
Req. No. 2407 	Page 10  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
contains any quantity of the following substa nces having stimulant 
or depressant effect on the cent ral nervous system: 
1.  Fenethylline; 
2.  Mecloqualone; 
3.  N-ethylamphetamine; 
4.  Methaqualone; 
5.  Gamma-Hydroxybutyric Acid, also known a s GHB, gamma-
hydroxybutyrate, 4-hydroxybutyrate, 4-hydroxybutanoic acid, sodium 
oxybate, and sodium oxybutyrate; 
6. Gamma-Butyrolactone (GBL) as packaged, marketed, 
manufactured or promoted for human consumption, with the exception 
of legitimate food add itive and manufacturing purposes; 
7.  Gamma Hydroxyvalerate (G HV) as packaged, marketed, or 
manufactured for human c onsumption, with the exception of legitimate 
food additive and manufacturing purposes ; 
8.  Gamma Valerolactone (GVL) as packaged, marketed , or 
manufactured for human consumption, with the exception of l egitimate 
food additive and manufacturing purposes; 
9. 1,4 Butanediol (1,4 BD or BDO) as packaged, marketed, 
manufactured, or promoted for human consumption with the exception 
of legitimate manufacturing purposes; or 
10.  N-ethylpentylone. 
E.  1.  The following industrial uses of Gamma -Butyrolactone, 
Gamma Hydroxyvalerate, Gamma Valerolactone, or 1,4 Butanediol are   
 
 
Req. No. 2407 	Page 11  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
excluded from all schedule s of controlled substan ces under this 
title: 
a. pesticides, 
b. photochemical etching, 
c. electrolytes of small batter ies or capacitors, 
d. viscosity modifiers in polyureth ane, 
e. surface etching of metal coated plastics, 
f. organic paint disbursements for water soluble inks, 
g. pH regulators in the dyeing of wool and polyamide 
fibers, 
h. foundry chemistry as a catalyst d uring curing, 
i. curing agents in many coating systems based on 
urethanes and amides, 
j. additives and flavoring agents in food, confection ary, 
and beverage products, 
k. synthetic fiber and clothing production, 
l. tetrahydrofuran production, 
m. gamma butyrolactone production, 
n. polybutylene terephthalate res in production, 
o. polyester raw materials for polyurethane elastomers 
and foams, 
p. coating resin raw materi al, and 
q. as an intermediate in the manufacture of other 
chemicals and pharmaceuticals.   
 
 
Req. No. 2407 	Page 12  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
2.  At the request of any person, the Director may exempt a ny 
other product containing Gamma -Butyrolactone, Gamma Hydroxyvalerate, 
Gamma Valerolactone, or 1,4 Butanedi ol from being included as a 
Schedule I controlled substance if such product is labeled, 
marketed, manufactured and distributed for legitimate indust rial use 
in a manner that reduces or eliminates the likelihood of abuse. 
3.  In making a determination regar ding an industrial product, 
the Director, after notice and hearing, shall consider the 
following: 
a. the history and current pattern of abuse, 
b. the name and labeling of the product, 
c. the intended manner of distribution, advertisi ng and 
promotion of the product, and 
d. other factors as may be relevant to and consistent 
with the public health and safety. 
4.  The hearing shall be held in accordance w ith the procedures 
of the Administrative Procedures Act. 
F.  Any material, compound, mixture, or preparation , whether 
produced directly or indirectly from a substance of vegetable origin 
or independently by means of chemical synthesis, or by a combination 
of extraction and chemical synthesis, that contains any quantity of 
the following substances, or that contai ns any of their salts, 
isomers, and salts of isomers when the existence of these salts,   
 
 
Req. No. 2407 	Page 13  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
isomers, and salts of isomers is possible within the specifi c 
chemical designation: 
1.  JWH-004; 
2.  JWH-007; 
3.  JWH-009; 
4.  JWH-015; 
5.  JWH-016; 
6.  JWH-018; 
7.  JWH-019; 
8.  JWH-020; 
9.  JWH-030; 
10.  JWH-046; 
11.  JWH-047; 
12.  JWH-048; 
13.  JWH-049; 
14.  JWH-050; 
15.  JWH-070; 
16.  JWH-071; 
17.  JWH-072; 
18. JWH-073; 
19.  JWH-076; 
20.  JWH-079; 
21.  JWH-080; 
22.  JWH-081;   
 
 
Req. No. 2407 	Page 14  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
23.  JWH-082; 
24.  JWH-094; 
25.  JWH-096; 
26.  JWH-098; 
27.  JWH-116; 
28.  JWH-120; 
29.  JWH-122; 
30.  JWH-145; 
31.  JWH-146; 
32.  JWH-147; 
33.  JWH-148; 
34.  JWH-149; 
35.  JWH-150; 
36.  JWH-156; 
37.  JWH-167; 
38.  JWH-175; 
39.  JWH-180; 
40.  JWH-181; 
41.  JWH-182; 
42.  JWH-184; 
43.  JWH-185; 
44. JWH-189; 
45.  JWH-192; 
46.  JWH-193;   
 
 
Req. No. 2407 	Page 15  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
47.  JWH-194; 
48.  JWH-195; 
49.  JWH-196; 
50.  JWH-197; 
51.  JWH-198; 
52.  JWH-199; 
53.  JWH-200; 
54.  JWH-201; 
55.  JWH-202; 
56.  JWH-203; 
57.  JWH-204; 
58.  JWH-205; 
59.  JWH-206; 
60.  JWH-207; 
61.  JWH-208; 
62.  JWH-209; 
63.  JWH-210; 
64.  JWH-211; 
65.  JWH-212; 
66.  JWH-213; 
67.  JWH-234; 
68.  JWH-235; 
69. JWH-236; 
70.  JWH-237;   
 
 
Req. No. 2407 	Page 16  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
71.  JWH-239; 
72.  JWH-240; 
73.  JWH-241; 
74.  JWH-242; 
75.  JWH-243; 
76.  JWH-244; 
77.  JWH-245; 
78.  JWH-246; 
79.  JWH-248; 
80.  JWH-249; 
81.  JWH-250; 
82.  JWH-251; 
83.  JWH-252; 
84.  JWH-253; 
85.  JWH-262; 
86.  JWH-292; 
87.  JWH-293; 
88.  JWH-302; 
89.  JWH-303; 
90.  JWH-304; 
91.  JWH-305; 
92.  JWH-306; 
93.  JWH-307; 
94.  JWH-308;   
 
 
Req. No. 2407 	Page 17  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
95.  JWH-311; 
96.  JWH-312; 
97.  JWH-313; 
98.  JWH-314; 
99.  JWH-315; 
100.  JWH-316; 
101.  JWH-346; 
102.  JWH-348; 
103.  JWH-363; 
104.  JWH-364; 
105.  JWH-365; 
106.  JWH-367; 
107.  JWH-368; 
108.  JWH-369; 
109.  JWH-370; 
110.  JWH-371; 
111.  JWH-373; 
112.  JWH-386; 
113.  JWH-387; 
114.  JWH-392; 
115.  JWH-394; 
116.  JWH-395; 
117.  JWH-397; 
118.  JWH-398;   
 
 
Req. No. 2407 	Page 18  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
119.  JWH-399; 
120.  JWH-400; 
121.  JWH-412; 
122.  JWH-413; 
123.  JWH-414; 
124.  JWH-415; 
125.  CP-55, 940; 
126.  CP-47, 497; 
127.  HU-210; 
128.  HU-211; 
129.  WIN-55, 212-2; 
130.  AM-2201; 
131.  AM-2233; 
132.  JWH-018 adamantyl-carboxamide; 
133.  AKB48; 
134.  JWH-122 N-(4-pentenyl)analog; 
135.  MAM2201; 
136.  URB597; 
137.  URB602; 
138.  URB754; 
139.  UR144; 
140.  XLR11; 
141.  A-796,260; 
142.  STS-135;   
 
 
Req. No. 2407 	Page 19  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
143.  AB-FUBINACA; 
144.  AB-PINACA; 
145.  PB-22; 
146.  AKB48 N-5-Fluorpentyl; 
147.  AM1248; 
148.  FUB-PB-22; 
149.  ADB-FUBINACA; 
150.  BB-22; 
151.  5-Fluoro PB-22; or 
152.  5-Fluoro AKB-48. 
G.  In addition to those substances listed in subsection F of 
this section, unless specifically excepted or unless listed in 
another schedule, any material, compound, mixture, or preparation 
which contains any quantity of a synthetic cannabinoid found to be 
in any of the follow ing chemical groups: 
1.  Naphthoylindoles: any compound containing a 3 -(1-
naphthoyl)indole structure with or without substitution at the 
nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalk yl, 
alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl , halobenzyl, 1-
(N-methyl-2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-
2-pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl, 
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or 
halophenyl group, whether or not further substituted on the indole 
ring to any extent, and whether or not substituted on the naphthyl   
 
 
Req. No. 2407 	Page 20  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
ring to any extent.  Naphthoylindoles include, but are not limited 
to: 
a. 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-
200), 
b. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201), 
c. 1-pentyl-3-(1-naphthoyl)indole (JWH -018), 
d. 1-butyl-3-(1-naphthoyl)indole (JWH-073), 
e. 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH -081), 
f. 1-propyl-2-methyl-3-(1-naphthoyl)indole (JWH -015), 
g. 1-hexyl-3-(1-naphthoyl)indole (JWH -019), 
h. 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH -122), 
i. 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210), 
j. 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH -398), 
k. 1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007), 
l. 1-pentyl-3-(7-methoxy-1-naphthoyl)indole (JWH-164), 
m. 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole 
(JWH-098), 
n. 1-pentyl-3-(4-fluoro-1-naphthoyl)indole (JWH-412), 
o. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(1-
naphthoyl)indole (AM -1220), 
p. 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole 
(MAM-2201), or 
q. 1-(4-cyanobutyl)-3-(1-naphthoyl)indole (AM -2232);   
 
 
Req. No. 2407 	Page 21  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
2.  Naphthylmethylindoles: any compound c ontaining a 1H-indol-3-
yl-(1-naphthyl)methane structure with or without substitution a t the 
nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, 
alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -
(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-
2-pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl, 
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or 
halophenyl group, whether or not further substituted on the indole 
ring to any extent, and whether o r not substituted on the naphthyl 
ring to any extent.  Naphthylmethylindoles include, but are not 
limited to, (1-pentylindol-3-yl)(1-naphthyl)methane (JWH-175); 
3.  Naphthoylpyrroles: any compound containing a 3 -(1-
naphthoyl)pyrrole structure with or witho ut substitution at the 
nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, 
cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 
halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2 -(4-
morpholinyl)ethyl, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
morpholinyl)methyl, (tetrahydropyran -4-yl)methyl, 1-methylazepanyl, 
phenyl, or halophenyl group, whether or not further substituted on 
the pyrrole ring to any extent, and whether or not substituted on 
the naphthyl group to an y extent.  Naphthoylpyrroles include, but 
are not limited to: 
a. 1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (J WH-147),   
 
 
Req. No. 2407 	Page 22  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
b. 1-pentyl-5-(2-methylphenyl)-3-(1-naphthoyl)pyrrole 
(JWH-370), 
c. 1-pentyl-3-(1-naphthoyl)pyrrole (JWH -030), or 
d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole (JWH -147); 
4.  Naphthylideneindenes: any compound containing a 1 -(1-
naphthylmethylene)indene structure with or without substitution at 
the 3-position of the indene ring by an alkyl, haloalkyl, 
cyanoalkyl, alkenyl, cycloalkylmethyl, cycloal kylethyl, benzyl, 
halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2 -(4-
morpholinyl)ethyl, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
morpholinyl)methyl, (tetrahydropyr an-4-yl)methyl, 1-methylazepanyl, 
phenyl, or halophenyl group, whether or not further substituted on 
the indene group to any extent, and whether or not substituted on 
the naphthyl group to any extent.  Naphthylmethylindenes include, 
but are not limited to, (1-[(3-pentyl)-1H-inden-1-
ylidene)methyl]naphthalene (JWH -176); 
5.  Phenylacetylindoles: any compound conta ining a 3-
phenylacetylindole structure with or without substitution at the 
nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl, 
alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -
(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
2-pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl, 
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or 
halophenyl group, whether or not further substituted on the indole   
 
 
Req. No. 2407 	Page 23  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
ring to any extent, and whethe r or not substituted on the phenyl 
ring to any extent.  Phenylacetylindoles include, but are not 
limited to: 
a. 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH -250), 
b. 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole 
(RCS-8), 
c. 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH -203), 
d. 1-pentyl-3-(2-methylphenylacetyl)indole (JWH -251), 
e. 1-pentyl-3-(4-methoxyphenylacetyl)indole (JWH-201), or 
f. 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH-302); 
6.  Cyclohexylphenols: any compound containing a 2 -(3-
hydroxycyclohexyl)phenol struc ture with or without substitution at 
the 5-position of the phenolic ring by an alkyl, haloalky l, 
cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylet hyl, benzyl, 
halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2 -(4-
morpholinyl)ethyl, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- 
morpholinyl)methyl, (tetrahydropyran -4-yl)methyl, 1-methylazepanyl, 
phenyl, or halophenyl group, and whether or not further substituted 
on the cyclohexyl ring to any extent .  Cyclohexylphenols include, 
but are not limited to: 
a. 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-
hydroxycyclohexyl]-phenol (CP-47,497),   
 
 
Req. No. 2407 	Page 24  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
b. 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-
phenol (cannabicyclohexanol; CP-47,497 C8 homologue), 
or 
c. 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-
hydroxypropyl)cyclohexyl]-phenol (CP 55, 940); 
7.  Benzoylindoles: any compound conta ining a 3-(benzoyl)indole 
structure with or without substitution at the nitrogen atom of the 
indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, 
cycloalkylmethyl, cycloalkylethyl, ben zyl, halobenzyl, 1-(N-methyl-
2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1-(N-methyl-2-
pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, 
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or 
halophenyl group, whether or not further substituted on the indole 
ring to any extent, and whether or not substituted on the phenyl 
group to any extent.  Benzoylindoles include, but are not limited 
to: 
a. 1-pentyl-3-(4-methoxybenzoyl)indole (RCS -4), 
b. 1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-
methoxybenzoyl)indole (Pravadoline or WIN 48, 098), 
c. 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM -694), 
d. 1-pentyl-3-(2-iodobenzoyl)indole (AM -679), or 
e. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(2-
iodobenzoyl)indole (AM -2233);   
 
 
Req. No. 2407 	Page 25  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
8.  Cyclopropoylindoles: Any compound containing a 3-
(cyclopropoyl)indole structure with substitutio n at the nitrogen 
atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, 
cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-
2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl, 
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or 
halophenyl group, whether or not further substituted in the indole 
ring to any extent and whether or not substituted in t he 
cyclopropoyl ring to any extent .  Cyclopropoylindoles inclu de, but 
are not limited to: 
a. 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole 
(UR-144), 
b. 1-(5-chloropentyl)-3-(2,2,3,3-
tetramethylcyclopropoyl)indole (5Cl -UR-144), or 
c. 1-(5-fluoropentyl)-3-(2,2,3,3-
tetramethylcyclopropoyl)indole (XLR11); 
9.  Indole Amides:  Any compound containin g a 1H-Indole-3-
carboxamide structure with or without substitution at the nitrogen 
atom of the indole ring by an alkyl, haloalkyl, cyanoalk yl, alkenyl, 
cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-
2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1-(N-methyl-2-
pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl, 
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or   
 
 
Req. No. 2407 	Page 26  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
halophenyl group, whethe r or not substituted at the carboxamide 
group by an adamantyl, naphthyl, phenyl, benzyl, quino linyl, 
cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not 
further substituted in the indole, adamantyl, naphthy l, phenyl, 
pyrrole, quninolinyl, or cycloalkyl rings t o any extent.  Indole 
Amides include, but are not limited to: 
a. N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide 
(2NE1), 
b. N-(1-adamantyl)-1-(5-fluoropentyl-1H-indole-3-
carboxamide (STS-135), 
c. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
indole-3-carboxamide (ADBICA), 
d. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-
fluoropentyl)-1H-indole-3-carboxamide (5F-ADBICA), 
e. N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide 
(NNE1), 
f. 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-
carboxamide (5F-NNE1), 
g. N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006), 
or 
h. N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide 
(5F-SDB-006);   
 
 
Req. No. 2407 	Page 27  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
10.  Indole Esters:  Any compound containing a 1H -Indole-3-
carboxylate structure with or without substitution at the nitrogen 
atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, 
cycloalkylmethyl, cycloalkylet hyl, benzyl, halobenzyl, 1 -(N-methyl-
2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-2-
pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl, 
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or 
halophenyl group, whet her or not substituted at the carboxylate 
group by an adamantyl, naphthy l, phenyl, benzyl, quinolinyl, 
cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not 
further substituted in the in dole, adamantyl, naphthyl, phenyl, 
pyrrole, quinolinyl, or cycloalkyl rings to any extent .  Indole 
Esters include, but are not limited to: 
a. quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-
22), 
b. quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate (5F-PB-22), 
c. quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-
carboxylate (BB-22), 
d. naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-
carboxylate (FDU-PB-22), or   
 
 
Req. No. 2407 	Page 28  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
e. naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate (NM2201); 
11.  Adamantanoylindoles:  Any compound containing an 
adamantanyl-(1H-indol-3-yl)methanone structure with or without 
substitution at the nitrogen atom of the indole ring by an alkyl, 
haloalkyl, cyanoalkyl, alkenyl, cycloalkylmet hyl, cycloalkylethyl, 
benzyl, halobenzyl, 1 -(N-methyl-2-piperidinyl)methyl, 2 -(4-
morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3- 
morpholinyl)methyl, (tetrahydropyran -4-yl)methyl, 1-methylazepanyl, 
phenyl, or halophenyl group, whether o r not further substituted in 
the indole ring to any extent and whether or not substituted in t he 
adamantyl ring to any extent .  Adamantanoylindoles include, but are 
not limited to: 
a. adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H-
indol-3-yl]methanone (AM1248), or 
b. adamantan-1-yl-(1-pentyl-1H-indol-3-yl)methanone (AB-
001); 
12.  Carbazole Ketone: Any compound containing (9H -carbazole-3-
yl) methanone structure with or without substitution at the nitrogen 
atom of the carbazole r ing by an alkyl, haloal kyl, cyanoalkyl, 
alkenyl, cycloalkylmeth yl, cycloalkylethyl, benzyl, halobenzyl, 1 -
(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-
2-pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl, 
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or   
 
 
Req. No. 2407 	Page 29  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
halophenyl group, with substi tution at the carbon of the methanone 
group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, 
cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not 
further substituted at the carbazole, adamantyl, naphthyl, phenyl, 
pyrrole, quinolinyl, or cycloalkyl rings to any extent .  Carbazole 
Ketones include, but are not limited to, na phthalen-1-yl(9-pentyl-
9H-carbazol-3-yl)methanone (EG-018); 
13.  Benzimidazole Ketone :  Any compound containing 
(benzimidazole-2-yl) methanone structure with or without 
substitution at either nitrogen atom of the benzimidazole ring b y an 
alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, 
cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-2-
piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-2-
pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl, 
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, pheny l, or 
halophenyl group, with substituti on at the carbon of the methanone 
group by an adamantyl , naphthyl, phenyl, benzyl, quinolinyl, 
cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not 
further substituted in the benzimidazole, adamantyl, naphthyl,   
 
 
Req. No. 2407 	Page 30  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent .  
Benzimidazole Ketones include, but are not limited to: 
a. naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-
l)methanone (JWH-018 benzimidazole analog), or 
b. (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-
yl)(naphthalen-1-yl)methanone (FUBIMINA); and 
14.  Modified by Replacement :  any compound defined in this 
subsection that is modified by replacement of a carbon with nitrogen 
in the indole, naphthyl, indene, benzimidazole, or carbazole ring. 
H.  Any prescription drug approved by the federal Food and Drug 
Administration under the pr ovisions of Section 505 of the Federal 
Food, Drug and Cosmetic Act , Title 21 of the United States Code, 
Section 355, that is designated, rescheduled or del eted as a 
controlled substance under federal law by the United States Drug 
Enforcement Administration shall be exc luded from Schedule I a nd 
shall be prescribed, distributed , dispensed or used in accordance 
with federal law upon the issuance of a notice, final rule or 
interim final rule by the United States Drug Enforcement 
Administration designating, rescheduling or deleting as a controlled 
substance such a drug product unde r federal law, unless and until 
the Board of Pharmacy takes action pursuant to Section 2 -201 of this 
title.  If the Board of Pharmacy does not take action pursuant to 
Section 2-201 of this title, the drug product shall be deemed to be 
designated, reschedul ed or deleted as a controlled substance in   
 
 
Req. No. 2407 	Page 31  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
accordance with federal law and in compliance with the Uniform 
Controlled Dangerous Substances Act . 
SECTION 2.  This act shall become effective November 1, 2022. 
 
58-2-2407 BG 12/30/2021 9:02:27 AM